Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Authors
Keywords
-
Journal
Expert Review of Endocrinology & Metabolism
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2022-08-06
DOI
10.1080/17446651.2022.2110864
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The interplay of thyroid hormones and the immune system – where we stand and why we need to know about it
- (2022) Christina Wenzek et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Association of thyroid function with insulin resistance: data from two population-based studies
- (2022) Dominik Spira et al. European Thyroid Journal
- Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
- (2022) Tobias Puengel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Breakthroughs in therapies for NASH and remaining challenges
- (2022) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks
- (2022) Stephen Harrison et al. JOURNAL OF HEPATOLOGY
- THR‐ß agonism improves disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
- (2021) Aimo Kannt et al. BRITISH JOURNAL OF PHARMACOLOGY
- Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis (nash) in five european countries in 2018: A cost‐of‐illness analysis
- (2021) Jörn M. Schattenberg et al. LIVER INTERNATIONAL
- Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment
- (2021) Dotan Moskovich et al. ONCOGENE
- Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
- (2021) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD
- (2021) Andrea Caddeo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Advancing the global public health agenda for NAFLD: a consensus statement
- (2021) Jeffrey V. Lazarus et al. Nature Reviews Gastroenterology & Hepatology
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
- (2021) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Fibrosis Development in NASH
- (2020) Robert F. Schwabe et al. GASTROENTEROLOGY
- Thyroid Function and the Risk of Fibrosis of the Liver, Heart, and Lung in Humans: A Systematic Review and Meta-Analysis
- (2020) Arjola Bano et al. THYROID
- Potential role of two novel agonists of thyroid hormone receptor‐β on liver regeneration
- (2020) Andrea Perra et al. CELL PROLIFERATION
- CD5L Constitutes a Novel Biomarker for Integrated Hepatic Thyroid Hormone Action
- (2020) Sebastian Nock et al. THYROID
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
- (2020) Joeri Lambrecht et al. EXPERT OPINION ON PHARMACOTHERAPY
- Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
- (2020) Tracey G Simon et al. GUT
- A deep proteome and transcriptome abundance atlas of 29 healthy human tissues
- (2019) Dongxue Wang et al. Molecular Systems Biology
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study
- (2019) Debashis Haldar et al. JOURNAL OF HEPATOLOGY
- Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis
- (2019) Paul Manka et al. DIGESTIVE DISEASES AND SCIENCES
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia (GSD Ia)
- (2019) Jin Zhou et al. THYROID
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Healthcare Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease are Nearly Twice Those of Matched Controls
- (2019) H. Hagström et al. Clinical Gastroenterology and Hepatology
- Thyroid hormone effects on glucose disposal in patients with insulin receptor mutations
- (2019) Yevgeniya S Kushchayeva et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis
- (2019) Massimiliano Runfola et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- New drugs for NAFLD: lessons from basic models to the clinic
- (2019) Katharina C. Reimer et al. Hepatology International
- Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
- (2018) Zobair Younossi et al. Clinical Gastroenterology and Hepatology
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
- (2018) Eveline Bruinstroop et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
- (2018) Ana Ruth Araújo et al. LIVER INTERNATIONAL
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis
- (2018) Zeqi Guo et al. DIGESTIVE AND LIVER DISEASE
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- An update on the recent advances in antifibrotic therapy
- (2018) Frank Tacke et al. Expert Review of Gastroenterology & Hepatology
- A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism
- (2018) Leonidas H. Duntas et al. Frontiers in Endocrinology
- Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
- (2018) Fasiha Kanwal et al. GASTROENTEROLOGY
- Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis
- (2018) Christin Krause et al. Endocrine Connections
- A Thyroid Hormone–Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy
- (2017) Meredith D. Hartley et al. ENDOCRINOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function
- (2017) Guoying Yu et al. NATURE MEDICINE
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo
- (2017) G. Sebastian Hönes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity
- (2017) Michael W Hornung et al. TOXICOLOGICAL SCIENCES
- Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease
- (2016) Brian Finan et al. CELL
- AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
- (2016) Massimiliano Gasparrini et al. CURRENT DRUG TARGETS
- Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
- (2016) Pegah Golabi et al. Health and Quality of Life Outcomes
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study
- (2016) Arjola Bano et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses
- (2016) Elvira Alonso-Merino et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atherogenic Lipoproteins in Subclinical Hypothyroidism and Their Relationship with Hepatic Lipase Activity: Response to Replacement Treatment with Levothyroxine
- (2016) Gabriela Brenta et al. THYROID
- Resistance to thyroid hormone due to defective thyroid receptor alpha
- (2015) Carla Moran et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism
- (2014) Brittany N. Bohinc et al. ENDOCRINOLOGY
- Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome
- (2014) Bo Angelin et al. JOURNAL OF INTERNAL MEDICINE
- Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
- (2014) Martha J. Kelly et al. JOURNAL OF MEDICINAL CHEMISTRY
- Thyroid hormone receptors and resistance to thyroid hormone disorders
- (2014) Tânia M. Ortiga-Carvalho et al. Nature Reviews Endocrinology
- Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism
- (2014) Rohit A. Sinha et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
- (2014) Barbara Sjouke et al. Lancet Diabetes & Endocrinology
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
- (2014) Hannele Yki-Järvinen Lancet Diabetes & Endocrinology
- Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
- (2013) Rebecca Taub et al. ATHEROSCLEROSIS
- Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis
- (2013) Melanie Kahle et al. Molecular Metabolism
- Non-alcoholic fatty liver disease across the spectrum of hypothyroidism
- (2012) Goh Eun Chung et al. JOURNAL OF HEPATOLOGY
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes
- (2010) Yi Lin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- Obesity and thyroid function
- (2009) Thomas Reinehr MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes
- (2009) John D. Baxter et al. NATURE REVIEWS DRUG DISCOVERY
- Sobetirome: a case history of bench-to-clinic drug discovery and development
- (2008) Thomas S. Scanlan HEART FAILURE REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started